These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 21889518)

  • 41. WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent.
    Hughes ZA; Liu F; Platt BJ; Dwyer JM; Pulicicchio CM; Zhang G; Schechter LE; Rosenzweig-Lipson S; Day M
    Neuropharmacology; 2008 Jun; 54(7):1136-42. PubMed ID: 18423777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative analysis of the neurophysiological profile of group II metabotropic glutamate receptor activators and diazepam: effects on hippocampal and cortical EEG patterns in rats.
    Siok CJ; Cogan SM; Shifflett LB; Doran AC; Kocsis B; Hajós M
    Neuropharmacology; 2012 Jan; 62(1):226-36. PubMed ID: 21791219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABA(A) receptor subtypes.
    Smith KS; Rudolph U
    Neuropharmacology; 2012 Jan; 62(1):54-62. PubMed ID: 21810433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Translocator protein (18 kDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders.
    Nothdurfter C; Baghai TC; Schüle C; Rupprecht R
    Eur Arch Psychiatry Clin Neurosci; 2012 Nov; 262 Suppl 2():S107-12. PubMed ID: 22923187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological reversal of cognitive bias in the chick anxiety-depression model.
    Hymel KA; Sufka KJ
    Neuropharmacology; 2012 Jan; 62(1):161-6. PubMed ID: 21722654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GABAergic functions and depression: from classical therapies to herbal medicine.
    Leung JW; Xue H
    Curr Drug Targets CNS Neurol Disord; 2003 Dec; 2(6):363-74. PubMed ID: 14683464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience.
    Lüscher B; Möhler H
    F1000Res; 2019; 8():. PubMed ID: 31275559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GABAergic control of depression-related brain states.
    Luscher B; Fuchs T
    Adv Pharmacol; 2015; 73():97-144. PubMed ID: 25637439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders.
    Witkin JM; Lippa A; Smith JL; Jin X; Ping X; Biggerstaff A; Kivell BM; Knutson DE; Sharmin D; Pandey KP; Mian MY; Cook JM; Cerne R
    Pharmacol Biochem Behav; 2022 Feb; 213():173321. PubMed ID: 35041859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders.
    Engin E; Liu J; Rudolph U
    Pharmacol Ther; 2012 Nov; 136(2):142-52. PubMed ID: 22921455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Classical neurotransmitters and neuropeptides involved in major depression in a multi-neurotransmitter system: a focus on antidepressant drugs.
    Werner FM; Coveñas R
    Curr Med Chem; 2013; 20(38):4853-8. PubMed ID: 24083608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect.
    Pytka K; Dziubina A; Młyniec K; Dziedziczak A; Żmudzka E; Furgała A; Olczyk A; Sapa J; Filipek B
    Pharmacol Rep; 2016 Apr; 68(2):443-50. PubMed ID: 26922551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GABAergic and endocannabinoid dysfunction in anxiety - future therapeutic targets?
    Domschke K; Zwanzger P
    Curr Pharm Des; 2008; 14(33):3508-17. PubMed ID: 19075727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions.
    Hare BD; Duman RS
    Mol Psychiatry; 2020 Nov; 25(11):2742-2758. PubMed ID: 32086434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Much excitement about antidepressants, DBI and c-FOS.
    Barbaccia ML
    Pharmacol Res; 2011 Oct; 64(4):333-5. PubMed ID: 21683143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibiting neuroinflammation: The role and therapeutic potential of GABA in neuro-immune interactions.
    Crowley T; Cryan JF; Downer EJ; O'Leary OF
    Brain Behav Immun; 2016 May; 54():260-277. PubMed ID: 26851553
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GABA function in mood disorders: an update and critical review.
    Shiah IS; Yatham LN
    Life Sci; 1998; 63(15):1289-303. PubMed ID: 9768867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The GABAβ receptor as a target for antidepressant drug action.
    Ghose S; Winter MK; McCarson KE; Tamminga CA; Enna SJ
    Br J Pharmacol; 2011 Jan; 162(1):1-17. PubMed ID: 20735410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GABA System in Depression: Impact on Pathophysiology and Psychopharmacology.
    Della Vecchia A; Arone A; Piccinni A; Mucci F; Marazziti D
    Curr Med Chem; 2022; 29(36):5710-5730. PubMed ID: 34781862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anxioselective anxiolytics.
    Williams M
    J Med Chem; 1983 May; 26(5):619-28. PubMed ID: 6132997
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.